"John passed from natural causes at the age of 84 years old," K.C.'s defense investigator Kevin Faler tells PEOPLE, adding that "there was no foul play" Liza Esquibias is an Editorial Intern at ...

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

building what seem like miles of shelves for used books at Daedalus on the corner of Market and Fourth streets as well as the iconic bar at C&O on East Water Street. In 1999, the Washington Post ...

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate ...

As their love for each other blossomed, Lilly watched her marriage crumble as she attempted to dodge the glaring eyes on her shrinking romance. Following a bitter divorce, Ethan and Ariana went ...

John C. McGinley was in Kosovo doing a USO tour when he got a call that would change his plans for the holidays. “This offer came to me when I was at a camp filled with soldiers,” explains ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Bad news for Novo Nordisk (NVO 0.72%) Friday was good news for Eli Lilly (LLY 1.61%) and Viking Therapeutics (VKTX-3.18%), its two main rivals in the field of weight loss drugs. This morning ...